Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

By L. Saltz, J. Cox, C. Blanke, L. Rosen, L. Fehrenbacher, M. Moore, J. Maroun, S. Ackland, P. K. Locker, N. Pirotta and 2 more. New England Journal of Medicine, 2000

2,548 citations recorded by the source corpus.

Subfields: Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/d9c356ac5e87cad06e089150cef49cc53b095616

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Marshall
2. R. Wierzbicki
3. V. Ganju
4. M. Jeffery
5. Raoudha Soufi-Mahjoubi
6. M. Valdesi
7. G. Nettis
8. V. Leonardi

Citations in the corpus

• Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. (2005, result): “These findings were reported as negative prognostic factors in the analysis of previous experiences.(10,19) The FOLFOX4 regimen obtained a 34% response rate in our study.”
• Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. (2007, result): “Earlier randomized trials comparing infusional to bolus FU/LV suggested that infusional schedules offered both superior efficacy and tolerability.(1,2) In a previous Intergroup study of first-line therapy for metastatic colorectal cancer (N9741), an infusional schedule of FU/LV with oxaliplatin (FOL”